Scott Sagel
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 107 | 2026 | 1164 | 13.120 |
Why?
| | Aminophenols | 25 | 2026 | 204 | 5.010 |
Why?
| | Quinolones | 25 | 2026 | 204 | 4.330 |
Why?
| | Kartagener Syndrome | 25 | 2026 | 31 | 3.590 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 31 | 2026 | 373 | 3.520 |
Why?
| | Ciliary Motility Disorders | 16 | 2025 | 24 | 3.270 |
Why?
| | Benzodioxoles | 15 | 2026 | 164 | 3.060 |
Why?
| | Sputum | 27 | 2026 | 302 | 2.950 |
Why?
| | Chloride Channel Agonists | 16 | 2026 | 111 | 2.320 |
Why?
| | Inflammation | 17 | 2026 | 2915 | 1.930 |
Why?
| | Pyrazoles | 9 | 2026 | 516 | 1.770 |
Why?
| | Lung | 26 | 2025 | 4119 | 1.670 |
Why?
| | Pyrrolidines | 7 | 2026 | 126 | 1.640 |
Why?
| | Indoles | 9 | 2026 | 509 | 1.640 |
Why?
| | Pyridines | 8 | 2026 | 606 | 1.570 |
Why?
| | Anti-Bacterial Agents | 16 | 2025 | 1935 | 1.500 |
Why?
| | Respiratory Function Tests | 21 | 2024 | 543 | 1.500 |
Why?
| | Respiratory System Agents | 3 | 2022 | 22 | 1.410 |
Why?
| | Bronchiectasis | 4 | 2025 | 115 | 1.360 |
Why?
| | Biomarkers | 26 | 2026 | 4329 | 1.350 |
Why?
| | Pseudomonas Infections | 11 | 2025 | 229 | 1.280 |
Why?
| | Azithromycin | 7 | 2025 | 101 | 1.270 |
Why?
| | Genetic Testing | 7 | 2021 | 491 | 1.250 |
Why?
| | Cilia | 17 | 2025 | 171 | 1.250 |
Why?
| | Aminopyridines | 6 | 2022 | 128 | 1.240 |
Why?
| | Neonatal Screening | 5 | 2021 | 185 | 1.230 |
Why?
| | Child | 81 | 2026 | 22638 | 1.180 |
Why?
| | Lung Diseases | 6 | 2023 | 787 | 1.170 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 63 | 1.160 |
Why?
| | Meconium Ileus | 2 | 2026 | 12 | 1.140 |
Why?
| | Adolescent | 75 | 2026 | 22451 | 1.110 |
Why?
| | Forced Expiratory Volume | 17 | 2025 | 451 | 1.040 |
Why?
| | Anti-Inflammatory Agents | 4 | 2020 | 473 | 1.010 |
Why?
| | Drug Combinations | 12 | 2026 | 399 | 1.000 |
Why?
| | Mutation | 29 | 2022 | 4082 | 0.970 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 641 | 0.960 |
Why?
| | Trypsinogen | 3 | 2021 | 11 | 0.950 |
Why?
| | Deoxyribonuclease I | 1 | 2025 | 42 | 0.920 |
Why?
| | Saline Solution, Hypertonic | 1 | 2025 | 43 | 0.910 |
Why?
| | Female | 99 | 2026 | 79080 | 0.830 |
Why?
| | Disease Progression | 19 | 2025 | 2857 | 0.820 |
Why?
| | Humans | 141 | 2026 | 145625 | 0.820 |
Why?
| | Young Adult | 45 | 2026 | 14240 | 0.820 |
Why?
| | Male | 95 | 2026 | 73014 | 0.790 |
Why?
| | Vitamins | 2 | 2018 | 183 | 0.780 |
Why?
| | Prospective Studies | 31 | 2026 | 8087 | 0.730 |
Why?
| | Antioxidants | 3 | 2018 | 544 | 0.720 |
Why?
| | Leukocyte Elastase | 8 | 2026 | 75 | 0.720 |
Why?
| | Pseudomonas aeruginosa | 11 | 2023 | 392 | 0.690 |
Why?
| | Ethambutol | 1 | 2021 | 27 | 0.670 |
Why?
| | Breath Tests | 6 | 2026 | 77 | 0.660 |
Why?
| | Algorithms | 4 | 2021 | 1843 | 0.650 |
Why?
| | Rifampin | 1 | 2021 | 79 | 0.650 |
Why?
| | Child, Preschool | 35 | 2026 | 11888 | 0.620 |
Why?
| | Nitric Oxide | 6 | 2026 | 883 | 0.590 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 87 | 0.580 |
Why?
| | Quinolines | 5 | 2026 | 191 | 0.570 |
Why?
| | Longitudinal Studies | 15 | 2026 | 3005 | 0.570 |
Why?
| | Dyneins | 7 | 2024 | 34 | 0.550 |
Why?
| | Dietary Supplements | 3 | 2018 | 586 | 0.510 |
Why?
| | Malnutrition | 1 | 2018 | 86 | 0.510 |
Why?
| | C-Reactive Protein | 8 | 2022 | 427 | 0.510 |
Why?
| | Nontuberculous Mycobacteria | 3 | 2023 | 189 | 0.500 |
Why?
| | Hospitalization | 3 | 2025 | 2468 | 0.460 |
Why?
| | Adult | 46 | 2026 | 40821 | 0.460 |
Why?
| | Drug Discovery | 1 | 2016 | 153 | 0.450 |
Why?
| | United States | 22 | 2025 | 16041 | 0.450 |
Why?
| | Infant | 24 | 2026 | 10093 | 0.440 |
Why?
| | Leukocyte L1 Antigen Complex | 5 | 2022 | 40 | 0.440 |
Why?
| | Infant, Newborn | 17 | 2026 | 6449 | 0.440 |
Why?
| | Specimen Handling | 3 | 2025 | 178 | 0.440 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2023 | 339 | 0.430 |
Why?
| | Sweat | 5 | 2025 | 52 | 0.410 |
Why?
| | Metabolomics | 1 | 2019 | 737 | 0.400 |
Why?
| | Automation | 1 | 2014 | 104 | 0.400 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2022 | 90 | 0.390 |
Why?
| | Retrospective Studies | 21 | 2025 | 17291 | 0.390 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2010 | 25 | 0.390 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 399 | 0.370 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 127 | 0.370 |
Why?
| | Microbiota | 5 | 2023 | 724 | 0.360 |
Why?
| | Treatment Outcome | 16 | 2026 | 11744 | 0.360 |
Why?
| | Clinical Trials as Topic | 5 | 2015 | 1062 | 0.360 |
Why?
| | Respiratory System | 4 | 2019 | 150 | 0.360 |
Why?
| | Blood Glucose | 5 | 2025 | 2357 | 0.350 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2011 | 17 | 0.340 |
Why?
| | Tomography, X-Ray Computed | 7 | 2025 | 2766 | 0.340 |
Why?
| | Sensitivity and Specificity | 7 | 2021 | 1992 | 0.330 |
Why?
| | Staphylococcal Infections | 3 | 2019 | 396 | 0.330 |
Why?
| | Vitamin K Deficiency | 1 | 2010 | 9 | 0.330 |
Why?
| | Vitamin A Deficiency | 1 | 2010 | 23 | 0.320 |
Why?
| | Cohort Studies | 14 | 2025 | 6045 | 0.320 |
Why?
| | Cytokines | 6 | 2023 | 2079 | 0.320 |
Why?
| | Severity of Illness Index | 10 | 2024 | 2910 | 0.310 |
Why?
| | Otitis Media with Effusion | 2 | 2025 | 20 | 0.300 |
Why?
| | Bronchoscopy | 2 | 2008 | 227 | 0.300 |
Why?
| | Quality of Life | 5 | 2024 | 3187 | 0.300 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2009 | 5 | 0.290 |
Why?
| | Bronchitis | 1 | 2009 | 28 | 0.290 |
Why?
| | Lactoferrin | 1 | 2009 | 37 | 0.290 |
Why?
| | Muramidase | 1 | 2009 | 66 | 0.280 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 188 | 0.280 |
Why?
| | Proteomics | 3 | 2022 | 1202 | 0.270 |
Why?
| | Tomography | 2 | 2018 | 44 | 0.270 |
Why?
| | Diverticulum | 1 | 2007 | 14 | 0.260 |
Why?
| | Tracheal Diseases | 1 | 2007 | 15 | 0.260 |
Why?
| | Cough | 2 | 2025 | 123 | 0.250 |
Why?
| | Tracheoesophageal Fistula | 1 | 2007 | 38 | 0.250 |
Why?
| | Administration, Oral | 3 | 2018 | 867 | 0.250 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 365 | 0.250 |
Why?
| | Genotype | 10 | 2025 | 1866 | 0.250 |
Why?
| | Digestive System Surgical Procedures | 1 | 2007 | 111 | 0.240 |
Why?
| | Heterotaxy Syndrome | 2 | 2023 | 14 | 0.240 |
Why?
| | Bacteria | 5 | 2023 | 766 | 0.240 |
Why?
| | Reproductive Health | 2 | 2017 | 94 | 0.240 |
Why?
| | Phenotype | 8 | 2025 | 3186 | 0.230 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2025 | 104 | 0.230 |
Why?
| | Cyclopropanes | 1 | 2026 | 83 | 0.230 |
Why?
| | Proteins | 4 | 2024 | 1021 | 0.230 |
Why?
| | Pulmonary Atelectasis | 1 | 2025 | 15 | 0.230 |
Why?
| | Leukocyte Count | 5 | 2012 | 319 | 0.220 |
Why?
| | Middle Ear Ventilation | 1 | 2025 | 16 | 0.220 |
Why?
| | Hearing Loss, Conductive | 1 | 2025 | 24 | 0.220 |
Why?
| | Interleukin-8 | 7 | 2012 | 268 | 0.210 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 128 | 0.210 |
Why?
| | Age Factors | 5 | 2020 | 3321 | 0.210 |
Why?
| | Rhinitis | 2 | 2019 | 159 | 0.210 |
Why?
| | Glucose Tolerance Test | 5 | 2025 | 360 | 0.210 |
Why?
| | Chlorides | 3 | 2022 | 138 | 0.210 |
Why?
| | DNA, Bacterial | 4 | 2017 | 319 | 0.210 |
Why?
| | Probability | 3 | 2016 | 308 | 0.210 |
Why?
| | Case-Control Studies | 8 | 2026 | 3633 | 0.200 |
Why?
| | Situs Inversus | 1 | 2023 | 2 | 0.200 |
Why?
| | Oropharynx | 3 | 2015 | 46 | 0.200 |
Why?
| | Cytoskeletal Proteins | 4 | 2024 | 146 | 0.200 |
Why?
| | Models, Neurological | 1 | 2006 | 252 | 0.200 |
Why?
| | Sinusitis | 2 | 2019 | 220 | 0.200 |
Why?
| | Axonemal Dyneins | 4 | 2025 | 8 | 0.200 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1101 | 0.190 |
Why?
| | Mucociliary Clearance | 2 | 2021 | 44 | 0.190 |
Why?
| | Follow-Up Studies | 7 | 2018 | 5397 | 0.190 |
Why?
| | Metagenome | 3 | 2013 | 127 | 0.190 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 311 | 0.190 |
Why?
| | Fetal Diseases | 1 | 2024 | 192 | 0.190 |
Why?
| | Respiration | 2 | 2026 | 207 | 0.190 |
Why?
| | Monitoring, Immunologic | 1 | 2002 | 25 | 0.180 |
Why?
| | Respiration Disorders | 1 | 2023 | 78 | 0.180 |
Why?
| | Genetic Markers | 4 | 2016 | 337 | 0.180 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1361 | 0.180 |
Why?
| | Calreticulin | 1 | 2022 | 22 | 0.180 |
Why?
| | Uteroglobin | 1 | 2022 | 31 | 0.180 |
Why?
| | HMGB Proteins | 1 | 2022 | 16 | 0.180 |
Why?
| | Chemistry, Clinical | 1 | 2002 | 5 | 0.180 |
Why?
| | Serum Amyloid A Protein | 2 | 2019 | 32 | 0.180 |
Why?
| | Peptide Hydrolases | 1 | 2023 | 105 | 0.180 |
Why?
| | Bone Density | 1 | 2026 | 492 | 0.170 |
Why?
| | Hydrogen | 1 | 2022 | 73 | 0.170 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.170 |
Why?
| | Synapses | 1 | 2006 | 447 | 0.170 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 35 | 0.170 |
Why?
| | Body Mass Index | 5 | 2020 | 2446 | 0.170 |
Why?
| | Prognosis | 5 | 2018 | 4331 | 0.170 |
Why?
| | Desmosine | 2 | 2012 | 5 | 0.170 |
Why?
| | DNA Mutational Analysis | 5 | 2014 | 409 | 0.160 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5875 | 0.160 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.160 |
Why?
| | Disease Management | 3 | 2015 | 649 | 0.160 |
Why?
| | Leptin | 1 | 2022 | 247 | 0.160 |
Why?
| | Cross-Over Studies | 2 | 2021 | 612 | 0.160 |
Why?
| | Pregnancy | 5 | 2026 | 7217 | 0.150 |
Why?
| | Glucose | 2 | 2023 | 1051 | 0.150 |
Why?
| | Mycobacterium abscessus | 1 | 2021 | 110 | 0.150 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 318 | 0.150 |
Why?
| | Patient Acuity | 1 | 2019 | 46 | 0.150 |
Why?
| | Sleep Apnea, Central | 1 | 1999 | 13 | 0.150 |
Why?
| | Autonomic Nervous System Diseases | 1 | 1999 | 38 | 0.140 |
Why?
| | Proteome | 2 | 2022 | 520 | 0.140 |
Why?
| | Alleles | 4 | 2017 | 900 | 0.140 |
Why?
| | Antitubercular Agents | 1 | 2021 | 211 | 0.140 |
Why?
| | Pneumonia | 2 | 2017 | 633 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 178 | 0.140 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 774 | 0.140 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2097 | 0.140 |
Why?
| | Prevalence | 3 | 2025 | 2852 | 0.140 |
Why?
| | Nutritional Status | 2 | 2018 | 344 | 0.140 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2018 | 19 | 0.140 |
Why?
| | Air | 1 | 2018 | 44 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 590 | 0.140 |
Why?
| | Hypoglycemia | 1 | 2023 | 489 | 0.140 |
Why?
| | Oxidative Stress | 2 | 2018 | 1367 | 0.130 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 88 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 1223 | 0.130 |
Why?
| | Saliva | 2 | 2015 | 256 | 0.130 |
Why?
| | Hirschsprung Disease | 1 | 1999 | 93 | 0.130 |
Why?
| | Health Services Misuse | 1 | 2017 | 33 | 0.130 |
Why?
| | Reproductive Health Services | 1 | 2017 | 23 | 0.130 |
Why?
| | Double-Blind Method | 3 | 2018 | 2064 | 0.130 |
Why?
| | Neutrophils | 3 | 2015 | 1132 | 0.130 |
Why?
| | Clofazimine | 1 | 2017 | 15 | 0.130 |
Why?
| | Tobramycin | 2 | 2023 | 63 | 0.130 |
Why?
| | Insulin | 2 | 2025 | 2524 | 0.120 |
Why?
| | Coinfection | 2 | 2020 | 143 | 0.120 |
Why?
| | Lipids | 1 | 2022 | 715 | 0.120 |
Why?
| | Body Height | 1 | 2017 | 202 | 0.120 |
Why?
| | Axoneme | 2 | 2013 | 8 | 0.120 |
Why?
| | Neurons | 1 | 2006 | 1663 | 0.120 |
Why?
| | Immunologic Tests | 1 | 2016 | 16 | 0.120 |
Why?
| | Middle Aged | 16 | 2025 | 36359 | 0.120 |
Why?
| | Sexual Health | 1 | 2017 | 67 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 253 | 0.110 |
Why?
| | Body Weight | 1 | 2020 | 964 | 0.110 |
Why?
| | Spirometry | 4 | 2015 | 234 | 0.110 |
Why?
| | Exome | 5 | 2014 | 232 | 0.110 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 108 | 0.110 |
Why?
| | Targeted Gene Repair | 1 | 2015 | 1 | 0.110 |
Why?
| | Microtubule-Associated Proteins | 2 | 2013 | 184 | 0.110 |
Why?
| | Time Factors | 4 | 2018 | 7079 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 446 | 0.110 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 129 | 0.110 |
Why?
| | Patient Selection | 1 | 2019 | 720 | 0.110 |
Why?
| | Pedigree | 5 | 2013 | 507 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1790 | 0.110 |
Why?
| | Zebrafish | 3 | 2013 | 533 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2023 | 1247 | 0.110 |
Why?
| | Postoperative Complications | 1 | 2007 | 2962 | 0.110 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 25 | 0.100 |
Why?
| | Nasal Mucosa | 4 | 2019 | 112 | 0.100 |
Why?
| | Hyperglycemia | 1 | 2018 | 381 | 0.100 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2016 | 150 | 0.100 |
Why?
| | Homozygote | 3 | 2020 | 196 | 0.100 |
Why?
| | Antigens, Surface | 1 | 2013 | 155 | 0.100 |
Why?
| | Ubiquinone | 2 | 2010 | 36 | 0.100 |
Why?
| | Survival Rate | 2 | 2018 | 2078 | 0.100 |
Why?
| | Sexual Behavior | 1 | 2017 | 489 | 0.100 |
Why?
| | Intestine, Small | 1 | 2014 | 160 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 293 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 330 | 0.090 |
Why?
| | GTP-Binding Proteins | 1 | 2013 | 150 | 0.090 |
Why?
| | Linear Models | 3 | 2024 | 847 | 0.090 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 55 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 84 | 0.090 |
Why?
| | DNA | 2 | 2018 | 1418 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 101 | 0.090 |
Why?
| | Elastin | 1 | 2012 | 78 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 462 | 0.090 |
Why?
| | Proteolysis | 1 | 2012 | 174 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 667 | 0.090 |
Why?
| | Glycoproteins | 1 | 2013 | 355 | 0.080 |
Why?
| | Nasal Cavity | 1 | 2011 | 60 | 0.080 |
Why?
| | Turbinates | 1 | 2011 | 14 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 314 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1030 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2025 | 1125 | 0.080 |
Why?
| | Biomarkers, Pharmacological | 1 | 2010 | 26 | 0.080 |
Why?
| | Dinoprost | 1 | 2010 | 51 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2005 | 507 | 0.080 |
Why?
| | Biopsy | 4 | 2015 | 1073 | 0.080 |
Why?
| | Metagenomics | 2 | 2021 | 153 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 585 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1581 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 274 | 0.080 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 367 | 0.070 |
Why?
| | Morbidity | 2 | 2018 | 317 | 0.070 |
Why?
| | Chronic Disease | 2 | 2015 | 1824 | 0.070 |
Why?
| | Membrane Potentials | 2 | 2010 | 278 | 0.070 |
Why?
| | Canada | 2 | 2024 | 430 | 0.070 |
Why?
| | Pseudomonas | 2 | 2022 | 30 | 0.070 |
Why?
| | Exotoxins | 1 | 2008 | 16 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2009 | 328 | 0.070 |
Why?
| | Administration, Inhalation | 2 | 2023 | 567 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2623 | 0.070 |
Why?
| | Lung Injury | 1 | 2012 | 262 | 0.070 |
Why?
| | Heterozygote | 1 | 2009 | 310 | 0.070 |
Why?
| | Electric Impedance | 2 | 2018 | 108 | 0.070 |
Why?
| | ROC Curve | 2 | 2026 | 613 | 0.070 |
Why?
| | Peroxidase | 2 | 2022 | 168 | 0.060 |
Why?
| | Asthma | 3 | 2026 | 1800 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 727 | 0.060 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 38 | 0.060 |
Why?
| | RNA Precursors | 1 | 2008 | 155 | 0.060 |
Why?
| | Pregnancy Rate | 2 | 2017 | 83 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2015 | 771 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1467 | 0.060 |
Why?
| | Genomics | 2 | 2021 | 851 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2007 | 178 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3396 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2455 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 724 | 0.060 |
Why?
| | Tidal Volume | 1 | 2026 | 108 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 26 | 0.050 |
Why?
| | Audiometry, Pure-Tone | 1 | 2025 | 25 | 0.050 |
Why?
| | Tympanic Membrane Perforation | 1 | 2025 | 15 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2013 | 2783 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Incidence | 2 | 2025 | 2910 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 276 | 0.050 |
Why?
| | Cephalosporins | 1 | 2024 | 45 | 0.050 |
Why?
| | Needs Assessment | 2 | 2017 | 403 | 0.050 |
Why?
| | Colorado | 2 | 2018 | 4588 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 109 | 0.050 |
Why?
| | Reference Values | 2 | 2017 | 787 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2008 | 458 | 0.050 |
Why?
| | Vasodilator Agents | 1 | 2006 | 326 | 0.050 |
Why?
| | Microscopy, Electron | 2 | 2015 | 384 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2025 | 278 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2006 | 288 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 367 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 211 | 0.050 |
Why?
| | Symptom Assessment | 1 | 2024 | 137 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 843 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 494 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 54 | 0.050 |
Why?
| | Registries | 2 | 2025 | 2382 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10840 | 0.050 |
Why?
| | Glucagon | 1 | 2023 | 114 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 315 | 0.040 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 26 | 0.040 |
Why?
| | Constipation | 1 | 2022 | 98 | 0.040 |
Why?
| | Nucleotides | 1 | 2022 | 128 | 0.040 |
Why?
| | Computer Simulation | 1 | 2006 | 1014 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.040 |
Why?
| | Down Syndrome | 1 | 2007 | 529 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2020 | 103 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 133 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 721 | 0.040 |
Why?
| | Prediabetic State | 1 | 2023 | 250 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2017 | 1403 | 0.030 |
Why?
| | British Columbia | 1 | 2018 | 27 | 0.030 |
Why?
| | Fatal Outcome | 1 | 1999 | 302 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 973 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 730 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 59 | 0.030 |
Why?
| | Pilot Projects | 2 | 2017 | 1878 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 704 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 1999 | 291 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 395 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1342 | 0.030 |
Why?
| | Ontario | 1 | 2016 | 91 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 174 | 0.030 |
Why?
| | Microscopy, Video | 1 | 2015 | 23 | 0.030 |
Why?
| | Respiratory Therapy | 1 | 2015 | 25 | 0.030 |
Why?
| | Radiography | 1 | 2017 | 856 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 994 | 0.030 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2015 | 39 | 0.030 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 44 | 0.030 |
Why?
| | Staphylococcus | 1 | 2015 | 74 | 0.030 |
Why?
| | North America | 1 | 2015 | 299 | 0.030 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 43 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2015 | 130 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 6050 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1957 | 0.030 |
Why?
| | Counseling | 1 | 2017 | 403 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2016 | 303 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1531 | 0.030 |
Why?
| | Planarians | 1 | 2013 | 1 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2101 | 0.030 |
Why?
| | Chlamydomonas | 1 | 2013 | 2 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 901 | 0.020 |
Why?
| | Xenopus laevis | 1 | 2013 | 101 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2013 | 130 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 533 | 0.020 |
Why?
| | Cytoplasm | 1 | 2013 | 253 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2018 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2012 | 77 | 0.020 |
Why?
| | Computer Communication Networks | 1 | 2012 | 30 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.020 |
Why?
| | Placebos | 1 | 2012 | 190 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 132 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 198 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 376 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 345 | 0.020 |
Why?
| | Airway Remodeling | 1 | 2012 | 63 | 0.020 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 16 | 0.020 |
Why?
| | Biota | 1 | 2011 | 28 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 388 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2112 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 834 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2015 | 541 | 0.020 |
Why?
| | Autoantigens | 1 | 2013 | 426 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 288 | 0.020 |
Why?
| | Ion Channels | 1 | 2010 | 128 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2013 | 538 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 629 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 611 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 782 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 38 | 0.020 |
Why?
| | gamma-Tocopherol | 1 | 2007 | 8 | 0.020 |
Why?
| | beta Carotene | 1 | 2007 | 20 | 0.020 |
Why?
| | Mexico | 1 | 2008 | 232 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 151 | 0.020 |
Why?
| | Micelles | 1 | 2007 | 37 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 2239 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2013 | 1118 | 0.020 |
Why?
| | Biological Availability | 1 | 2007 | 146 | 0.020 |
Why?
| | Animals | 3 | 2013 | 38030 | 0.020 |
Why?
| | Leukocytes | 1 | 2008 | 301 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 751 | 0.010 |
Why?
| | Research Design | 1 | 2012 | 1139 | 0.010 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 60 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 926 | 0.010 |
Why?
| | Sulfones | 1 | 2006 | 127 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 1033 | 0.010 |
Why?
| | Aged | 2 | 2017 | 26251 | 0.010 |
Why?
| | Genetic Carrier Screening | 1 | 2004 | 31 | 0.010 |
Why?
| | Purines | 1 | 2006 | 188 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5574 | 0.010 |
Why?
| | Infant Care | 1 | 2004 | 43 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8351 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2591 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2835 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2004 | 159 | 0.010 |
Why?
|
|
Sagel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|